Russell Alan J, the Chief Scientific Officer of Edgewise Therapeutics , Inc. (NASDAQ:EWTX), executed a series of stock transactions recently, as detailed in a recent SEC filing. On February 5 and 6, ...
Behrad Derakhshan, the Chief Business Officer of Edgewise Therapeutics , Inc. (NASDAQ:EWTX), recently sold 10,000 shares of the company's common stock. The shares were sold at an average price of $30.
Edgewise Therapeutics has a 12 month low of $9.61 and a 12 month high of $38.12. The firm has a fifty day simple moving average of $29.65 and a 200 day simple moving average of $26.09. Get ...
In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent ...
Begin your TipRanks Premium journey today. Edgewise Therapeutics (EWTX) Company Description: Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery ...
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research ...
Shares of Edgewise Therapeutics (NASDAQ:EWTX) traded flat on Wednesday after Stifel launched its coverage with a Hold recommendation, indicating a balanced risk-reward profile for the muscle drug ...
Investors in Edgewise Therapeutics Inc (Symbol: EWTX) saw new options become available today, for the December 19th expiration. One of the key inputs that goes into the price an option buyer is ...
For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the share price soaring by 176%. Having said that, unprofitable companies are risky ...
Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...
We can readily understand why investors are attracted to unprofitable companies. For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the share ...